PALO ALTO, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Telik, Inc. announced that its quarterly conference call and webcast will be held on Thursday, February 9, 2006 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). The call will follow the release of Telik’s financial results for the fourth quarter and year ended December 31, 2005 earlier that day.
The conference call will be accessible via Telik’s website at www.telik.com or by telephone at 888-428-4479 or 612-288-0318. An archive of the conference call will be available on the Telik website from approximately 8:30 p.m. Eastern time on February 9 through February 16, 2006, or by telephone at 800-475-6701 or 320-365-3844, access code 818019.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA(R) (TLK286), a tumor-activated small molecule product candidate. TELCYTA is in three Phase 3 registration trials, ASSIST-1, ASSIST-2 and ASSIST-3, in advanced ovarian and non-small cell lung cancer. A second drug development candidate, TELINTRA(TM) (TLK199), is in Phase 2 clinical development in myelodysplastic syndrome. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
Telik, Inc.
CONTACT: Carol D. DeGuzman, Senior Director, Corporate Communications ofTelik, Inc., +1-650-845-7728, or cdeguzman@telik.com
Web site: http://www.telik.com/
